Wedbush analyst, Heather Behanna, cut her price target on PTC Therapeutics (NASDAQ: PTCT) to $27 from $65 after Translarna stumbles ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE